National Cancer Institute NCI Cancer Bulletin: A Trusted Source for Cancer Research News
November 27, 2012 • Volume 9 / Number 23

Info

Infographic: Benefits and Harms of PSA Screening for Prostate Cancer

As more has been learned about the benefits and harms of prostate-specific antigen (PSA) screening, organizations have begun to recommend against routine screening. Screening is a personal decision that, according to most experts, a man should make in consultation with his doctor, after he has been informed in detail about the potential benefits and harms.

The infographic below depicts the benefits and harms of PSA screening for prostate cancer. The estimates appeared in the U.S. Preventive Services Task Force Recommendation Statement, published July 17 in the Annals of Internal Medicine. The estimates were based on 13- and 11-year follow-up data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial and the European Randomized Study of Screening for Prostate Cancer. According to the two trials, the best evidence of possible benefit of PSA screening is in men aged 55 to 69.

Graphic showing the number of men who would experience benefits and harms if 1,000 men aged 55 to 69 were screened every 1 to 4 years for 10 years with a PSA test